$EVMN

Patel Jeegar Pravinkumar sold $33K of EVMN

Patel Jeegar Pravinkumar (Chief Scientific Officer) sold 1,488 shares of Evommune, Inc. (EVMN) at $22.50 on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Patel Jeegar Pravinkumar
Published Jun 25, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EVMN
Neutral
high confidence
Mentioned
$EVMN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVMNNeutralLow
01

Why it matters

The disclosure updates the insider’s holdings but does not introduce new company performance, product, trial, or regulatory information.

02

Market read

Traders may note the insider sale, but it is unlikely to materially change near-term valuation absent other catalysts.

03

What to watch

The sale size is modest and the plan is pre-arranged; without additional context (e.g., other concurrent sales, option exercises), the signal is weak.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-24 for a 2026-06-22 sale

Background

This is an SEC Form 4 insider transaction by Evommune’s Chief Scientific Officer.

Company-level read

Ticker impact

$EVMNNeutralHigh confidence
Context

Evommune CSO Patel Jeegar Pravinkumar sold 1,488 shares at $22.50 ($33,480) under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is a small, pre-arranged open-market sale by an officer with no accompanying new operational/regulatory/financial catalyst.

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Even pre-arranged 10b5-1 sales can coincide with private information, so traders may still watch for follow-on insider activity or guidance changes.

Key entities

  • Evommune, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Patel Jeegar Pravinkumar

    Chief Scientific Officer who sold shares under a pre-arranged 10b5-1 plan.

Related articles

$EVMNMed

Evommune, Inc. (EVMN): Results of Operations and Financial Condition

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial